Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | GSK3A | P49840 | 2/20 | 0.52 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.52 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.49 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.47 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.47 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.47 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.47 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.47 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.47 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.47 |
| ▸ | TYMP | P19971 | 4/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14943053 | 0.91 | LMNA (0.64) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL10017765 | 0.91 | LMNA (0.64) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL10048818 | 0.91 | LMNA (0.64) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL3150082 | 0.91 | LMNA (0.64) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL10001659 | 0.91 | LMNA (0.64) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL24191242 | 0.91 | LMNA (0.64) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL9658521 | 0.89 | ALDH1A1 (0.54) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL7060133 | 0.87 | ALDH1A1 (0.54) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL8970298 | 0.86 | ALDH1A1 (0.60) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL8970294 | 0.86 | ALDH1A1 (0.60) | ALDH1A1LMNATP53MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4008403-A1 | CYCLIC DI-NUCLEOTIDES COMPOUNDS FOR THE TREATMENT OF CANCER | Eisai R&D Management Co., Ltd. (JP) | 2022-06-08 | — | — | EP | disclosed |
| US-11339188-B2 | Compounds for the treatment of cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-05-24 | — | — | US | disclosed |
| EP-3582853-B1 | CYCLIC DI-NUCLEOTIDES COMPOUNDS FOR THE TREATMENT OF CANCER | EISAI R&D MAN CO LTD (JP) | 2021-11-17 | — | — | EP | disclosed |
| US-20200299321-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-09-24 | — | — | US | disclosed |
| US-20200055883-A1 | CYCLIC DI-NUCLEOTIDES DERIVATIVE FOR THE TREATMENT OF CANCER | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-02-20 | — | — | US | disclosed |
| US-20190345192-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-11-14 | — | — | US | disclosed |
| US-10246480-B2 | Compounds for the treatment of cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299321-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | TP53, MYC, CDC73 | ALDH1A1 286/4885LMNA 2684/4885TP53 1/4885 |
| US-11339188-B2 | Compounds for the treatment of cancer | TP53, MYC, CDC73 | ALDH1A1 286/4885LMNA 2684/4885TP53 1/4885 |
| US-20190345192-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | TP53, MYC, CDC73 | ALDH1A1 286/4885LMNA 2684/4885TP53 1/4885 |
| US-10246480-B2 | Compounds for the treatment of cancer | TP53, MYC, CDC73 | ALDH1A1 286/4885LMNA 2684/4885TP53 1/4885 |
| US-20200055883-A1 | CYCLIC DI-NUCLEOTIDES DERIVATIVE FOR THE TREATMENT OF CANCER | NME4, NME2, DPYD | ALDH1A1 1840/4885LMNA 2561/4885TP53 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.